PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Expert Opin Biol Ther. Author manuscript; available in PMC 2011 March 1.
Published in final edited form as:
PMCID: PMC2825571
NIHMSID: NIHMS169012

Teplizumab therapy for type 1 diabetes

Abstract

Importance of the field

Type 1 diabetes mellitus (T1D) is a T cell mediated autoimmune disease with selective destruction of β-cells. Immunological interventions are directed at arresting the loss of β-cell function with the promise that this will make it easier for patients to control their glucose levels.

Areas covered in this review

This review provides a summary of the preclinical and clinical research published between 1992 and 2009 using teplizumab and other anti-CD3 antibodies to arrest the loss of β-cell function in new onset T1D. Data from animal and human studies on the probable mechanism of action of teplizumab are also reviewed.

What the readers will gain

A broad perspective on the use of teplizumab in inducing disease specific tolerance.

Take home message

In phase I/II randomized control trials, in patients with new onset T1D, teplizumab slows the rate of loss of β-cell function over two years of follow up. Treated patients had better glycemic control and lower insulin requirements. Adverse events so far are mild and of limited duration. Phase III clinical trials are underway to confirm these results and to determine if two courses of drug have greater efficacy in arresting in loss of β-cell function.

Keywords: teplizumab, type 1 diabetes, immunologic tolerance, regulatory T cells, anti-CD3 antibody

1. Introduction

Type 1 diabetes (T1D) is a T cell mediated autoimmune disease with selective destruction of β-cells by auto reactive CD4+ and CD8+ T lymphocytes. In the non-obese diabetic (NOD) mouse model of T1D the disease can be transferred by infusing splenic CD4+ and CD8+ T cells into syngeneic immunocompetent recipients such as NOD neonates or adult irradiated NOD mice or NOD SCID mice [1]. An analogous human experiment is the development of T1D in recipients of bone marrow from donors with T1D [2]. Other immune cells apart from CD4+ and CD8+ T cells may also play a role in development of T1D. T regulatory cells may be important in controlling disease progression; and abnormal function and/or frequency of Fox-P3 expressing CD4+CD25+ Treg cells and IL4 and IL10 secreting Th2 and Tr1 cells in NOD mice and type 1 patients has been reported [3;4]. There is also data evidence implicating dendritic cells [5], macrophages [6;7] and B lymphocytes [8]. In NOD mice lacking B lymphocytes, the incidence of diabetes drops from 80 percent to 30 percent, and the disease develops a little later [8]. B lymphocyte deficient humans however, can still develop T1D providing convincing evidence that principal effector mechanisms are mediated by T cells [9].

2. The natural history of T1D

The autoimmune attack directed against β-cells occurs several years (5 years or more) before the clinical presentation of diabetes [10]. In the Diabetes Prevention Trial 1 (DPT1), loss of first-phase insulin secretion and confirmed islet autoantibodies (and lacking the protective HLA allele DQB1*0602) was associated with greater than a 50% risk of progressing to diabetes within the next 5 years [11;12]. Even after the diagnosis of diabetes there is still significant β-cell function and this explains why after treatment of the acute presentation there is a period of clinical remission – the “honeymoon phase” [13]. The decline in β-cell loss is often depicted as a linear decline but this is probably not true. Not only is there β-cell destruction but also some β-cell regeneration and the net decline reflects the balance between the two events [14]. It is likely that there is waxing and waning of the immunological destruction and acute loss may be followed by relative stability before further decline. The clinical remission after initial presentation is most likely due to recovery of insulin secretory capacity of β-cells present at diagnosis rather than due to regeneration of new β-cells. Unfortunately the remission is usually temporary and β-cell function declines so that many patients require full replacement doses of insulin within a few months. Immunological interventions have been directed both before the development of diabetes and after diagnosis in order to prevent decline in residual β-cell function.

3. Immunotherapy

Immunotherapeutic interventions in T1D have involved both antigen specific and non antigenic specific therapy [15;16].

3.1 Antigen specific therapy

Antigen specific therapies are directed at controlling the autoimmune process by inducing antigen specific tolerance. The rationale behind these interventions is to generate antigen specific regulatory T cells that induce anergy/deletion of autoreactive effector T cells [17;18]. One of the challenges in T1D is identifying the pathogenic epitopes at the initiation of disease. After the onset of the autoimmune injury, epitope spreading makes identifying specific target antigens difficult [19]. The antigens used as tolerogens for T1D have included insulin and glutamic acid decarboxylase (GAD) [11;20]. So far this approach has not been successful. The DPT1 study failed to show efficacy with parenteral or oral insulin [11] in subjects who were at high risk for developing diabetes. There was a suggestion that a subgroup of individuals with high titers of anti insulin antibodies might have benefited; and a study is in progress to explore this. Two aubcutaneous injections of alum formulated GAD did not prevent a decline in β-cell function in new onset patients with T1D [20]. There is also a current study using human proinsulin encoding DNA plasmid vaccine [21] in new onset T1D.

3.2 Non antigen specific immunotherapy

Broad spectrum immunosuppressive agents such as cyclosporine, azathioprine, prednisone and anti-thymocyte globulin that deplete or inactivate pathogenic T cells have been tried in new onset T1D to see if they would prolong the clinical remission [2227]. They did indeed decrease insulin requirements but the effect was modest and these drugs have both short and long term toxicity.

Even though non-antigen specific therapy is not directed at a specific population of pathogenic T cells, this is not to say that it cannot induce disease specific tolerance. Treatment with antiCD3 antibodies may be an example of such an approach (vide infra). The concept is of applying non-antigen specific therapy that targets activated T cells wherever they are in the body. Hopefully when you have new onset diabetes, activated T cells are present only in the pancreas and no where else in the body.

4. Anti-CD3 antibodies

In 1979, Kung and Goldstein developed a mouse hybridoma cell line producing a IgG2a monoclonal antibody (ORTHOCLONE, OKT3) against a T cell surface antigen that showed promise in preventing rejection after allograft transplantation [2831]. This OKT3 antibody was later identified as being specific to the ε chain of the CD3 complex which is the major signal transducing element of the T cell receptor[32].

The use of OKT3 in clinical use, however, was limited by its side effect of a “flu-like” syndrome consisting of high fever, chills, headache, and gastrointestinal symptoms (vomiting and diarrhea) and in severe cases pulmonary edema within hours of treatment [33]. This syndrome is due to OKT3 cross-linking the TCR/CD3 complex on the T cell surface and causing the T cell to release cytokines including tumor necrosis factor alpha (TNFα), interferon-γ, interleukins IL-2, IL-3, IL-4, IL-6, IL-10 and granulocyte-macrophage colony-stimulating factor. [3438]. Binding by Fc receptor bearing cells (such as monocytes) to the Fc portion of OKT3 enhances the T cell receptor/CD3 complex crosslinking and increases the severity of this cytokine release syndrome. F(ab’)2 fragments that lack the Fc portion do not result in as much cytokine release [3946]. This observation led to the development of FcR non-binding anti-CD3 antibodies. The T cell activation also varies with the isotype of the anti CD3 specific antibody - the IgG2a class appearing to have the strongest effect [4749]. OKT3, being a mouse monoclonal antibody results in development of human anti-mouse antibody that causes rapid clearance of injected OKT3 and reduces its efficacy. The solution to this problem is to humanize the antibody [39;40;50].

5. Humanized FcR non-binding anti CD3 specific antibodies

Two specific humanized FcR non-binding anti-CD3 antibodies have been studied in patients with T1D. hOKT3 γ1(Ala-Ala), (teplizumab), is a humanized version of the mouse monoclonal OKT3 antibody – retaining the same binding region of OKT3 but with amino acids at positions 234 and 235 of the human IgG1 Fc changed to alanine resulting in decreased Fc binding [35;44]. ChAglyCD3 or otelixizumab is a humanized version of a rat anti-CD3 monoclonal antibody lacking a crucial glycosylation site in the Fc portion resulting in decreased Fc binding [40]. These two antibodies appear to have decreased cytokine release potential because of the changes in the Fc regions but maintain their immunomodulatory effects.

6. Proposed mechanisms of immunomodulation by anti-CD3 antibodies

Studies in the diabetic NOD mice have provided insights in the mechanisms of action of anti-CD3 therapy in T1D: (i) there appears to be an induction of self tolerance because syngeneic islet grafts transplanted into anti-CD3 treated mice survive indefinitely; and continuous immunosuppression was not needed. Moreover, the tolerance is specific because mismatched skin allografts are normally rejected [41]; (ii) treated NOD mice are resistant to the transfer of diabetes by diabetogenic spleen cells suggesting a regulatory T cell function [51]; (iii) treatment is most effective when the mice just develop hyperglycemia and not in prediabetic younger animals suggesting that the drug works on effector cells that are at present at onset of disease. Despite these observations, the cellular mechanisms by which anti-CD3 antibodies turn off the autoimmune destruction are not well understood. After infusion of the anti CD3 antibody, there is clearance of the immunological infiltrate from the islets [41]. During this initial treatment phase there may apoptosis of activated T cells; antigenic immunomodulation of the T cell receptor complex; and altered trafficking. After treatment has been completed there is a return of the islet infiltrate, but it appears to be non destructive and confined to the periphery of the islets [41]. This altered immunological effect may reflect a resetting of T cell dependent active tolerogenic mechanisms [52;53] and several regulatory T cells and downstream signals have been implicated in this process. An induction of Foxp3+ CD4+CD25+ regulatory T cells [54;55] has been observed in pancreatic and mesenteric lymph nodes of treated mice [56]. The regulation appears to be via a transforming growth factor beta (TGFβ) mechanism because co-administration of TGFβ neutralizing antibody prevents the tolerizing effect of anti-CD3 therapy [52]. In the human clinical trials, a reduction in the CD4:CD8 ratio has been noted and this change seems to correlate with maintenance of C-peptide responses. The change in the ratio is not due to depletion of CD4 cells but due to an increase in a regulatory population of Foxp 3+CD8+CD25+ T cells [57].

7. Human trials with teplizumab and otelixizumab

In the phase I/II clinical trials, teplizumab and otelixizumab have been given to new onset T1D to determine whether these drugs will turn off the autoimmune process and prevent decline of residual β-cell function [5861].

In the first study [58], Herold and colleagues recruited 24 subjects with new onset T1D. Inclusion criteria included diagnosis of diabetes in the previous six weeks, ages 71/2 to 30 years of age and positive for one of the autoantibodies against β-cell antigens (anti-GAD, anti-islet cell, anti-ICA512, or anti-insulin antibodies). In this open label study, the 12 subjects randomized to test therapy were given daily infusions of teplizumab for 14 days. The control group underwent the same metabolic and immunologic studies as in the drug-treated group, but the patients did not receive anti-CD3 mAb and were not hospitalized. Outcomes included T-cell analysis, area under the curve (AUC) C-peptide response to mixed meal tolerance tests, and HbA1c (glycated hemoglobin A1c) levels. The treatment group had maintenance of AUC C-peptide responses for one year whereas the control group showed significant decline (p=0.01). In the treatment group, the AUC C-peptide was 111.5 ± 50.2 nmol/l at time 0 and 114.2 ± 90.6 nmol/l at 1 year. In the control group on the other hand, the AUC C-peptide was 133.2 ±50.7 nmol/l at time 0 and 66.7 ± 53 nmol/l at 1 year. In keeping with the maintained β-cell function, the treatment group had lower HbA1c levels and lower insulin requirements compared to the control group.

There was a transient reduction in the circulating lymphocytes with a nadir occurring five days after treatment with levels returning to normal two weeks after the last dose of the monoclonal antibody. The recovered lymphocytes are unlikely to be new T lymphocytes from the thymus because T receptor excision circles (TREC) - stable, nonreplicative DNA strands excised from T cells during TCR gene rearrangement in the thymus - were not present [62]. Clinical response was also associated with decreased CD4:CD8 ratio 30 days and 90 days after treatment. IL-6 and TNFα, were notably elevated after the second day treatment, but remained much lower than values typically associated with cytokine release syndrome. Other side effects included mild and moderate fever and anemia. A mild pruritic utricarial rash developed on the hand and occasionally the trunk and feet in about half of the treatment group. The rash appeared half way through the treatment course and resolved by day 30. Anti idiotypic antibodies developed in half of the treated group but were detectable in only one patient at one year.

A subsequent report evaluated this same cohort of patients but also included some additional subjects and reported their follow up data at 24 months – there were 24 subjects who got 12 to 14 day infusion of drug and 24 control subjects [37]. The analyses at 1 year of this larger cohort showed maintained AUC C-peptide in the treatment group (97.1 + 9.6 % of response at study entry) but significant decline in control group (53.1 + 7.6 % of response at study entry). In the second year however, there is gradual decline in AUC C-peptide responses in the treatment group but the values are still significantly higher compared to the control group (p<0.02). Thus at 24 months the AUC C peptide was ~ 80 pmol/ml/240 minutes in the treatment group and ~35 pmol/ml/230 minutes in the control group. The treatment group also had lower HbA1c levels and lower insulin requirements compared to the control group in this second year. The main conclusion from this 2 year follow up data is that teplizumab is effective in arresting the β-cell decline the first year but that this effect is not sustained and that in the second year a decline in β-cell occurs. Dr. Herold and colleagues also recently reported maintenance of C-peptide levels in 4 drug treated subjects (different cohort) followed up to 5 years [60].

Taken together, these different cohorts of patients indicate that one 12 to 14 day course of teplizumab attenuates the decline of β-cell function for at least two years and possibly five years. These studies with teplizumab can further be correlated with clinical data using the other humanized anti-CD3 antibody, otelixizumab.

Otelixizumab was evaluated in a similar study - 80 new T1D patients were randomly assigned to receive 6 days of otelixizumab or placebo infusions [61]. β-cell function was assessed measuring C-peptide release following glucagons injection. Patients receiving otelixizumab had higher levels of C-peptide compared to the placebo group for up to 18 months. This effect of the drug was more pronounced in patients whose β-cell function at baseline was in the 50th percentile or above. As with teplizumab treatment, treatment with otelixizumab did not completely arrest the decline in β-cell function and there was a gradual decline from 6 months to 18 months. The immune changes and adverse reactions were similar to those seen with teplizumab-transient lymphopenia, decreased CD4:CD8 ratio, headaches, gastrointestinal symptoms, arthralgias and myalgias, and rash. In addition, 30 of the patients in the treatment group reported a mononucleosis-like syndrome comprised of sore throat, fever, and cervical adenopathy [61]. In 21 of 22 patients with available samples, this syndrome was associated with a rise in EBV DNA that normalized between 6 and 12 weeks. This symptomatic reactivation of EBV was not reported with teplizumab therapy. Teplizumab patients, however, were younger and so fewer may have been EBV carriers. Also the cumulative dose of teplizumab used was lower than that used in the otlexizumab trial and this could have had an impact on EBV reactivation. The phase III studies with these two agents may provide additional information regarding the issue of EBV reactivation.

8. Potential use of teplizumab with other therapies

There is interest in combining teplizumab with other therapies. Teplizumab combined with standard therapy has been shown in a clinical trial to be effective in treating acute renal and renal-pancreas allograft rejection [63]. Hering and colleagues have also used teplizumab in combination with sirolimus and tacrolimus in islet transplantation with 4 of 6 subjects becoming insulin independent for 1 year [64;65]. It has also been proposed using teplizumab in combination with exenatide in new onset T1D. Teplizumab would turn off the autoimmune process and exenatide would reduce the rate of apoptosis resulting in an increase in β-cell mass and function [66].

9. Teplizumab in other autoimmune disorders

A phase I/II trial from 2002 examined the role of teplizumab in psoriatic arthritis [67]. In this trial, seven patients were treated with escalating doses over a period of 12–14 days. Six of the patients noted a decreased amount of inflamed joints and 63% noted reduction in joint pain.

10. Conclusion and Expert Opinion

A 12 to 14 day course of teplizumab therapy in new onset T1D results in stable β-cell function the first year after treatment and a gradual decline in the second year. C-peptide levels are higher in the treatment group than in the control group at all time points. Current clinical trials are administering two courses of drug (at diagnosis and 6 months later) with the idea that the second course will prevent the decline that occurs in the second and subsequent years.

Adverse events reported so far seem to be mild and of limited duration. Fever, headaches, myalgia, nausea and vomiting, and pruritic rash are the commonest reactions. All the patients have lymphopenia which recovers at about 1 month. A case of thrombocytopenia was reported.

In the study using otelixizumab, EBV reactivation with infectious mononucleosis type symptoms was reported. This has not been reported in the teplizumab trials but that may reflect differences in patient population and cumulative dose. There also have not been any reports of lymphoproliferative disorder. It should be pointed out, however, that only small number of patients has received the drug and follow up limited to two years. Studies of longer duration on larger number of subjects are necessary to evaluate long term safety.

The treated patients have better glucose control and lower insulin requirements even though the drug does not completely arrest the decline in β-cell function. The Diabetes Control and Complications Trial (DCCT) showed that having some β-cell function is associated with lower risk of hypoglycemia; better glycemic control; and lower rate of microvascular complications [68]. Long term follow up of the DCCT cohort also showed what is referred to as the legacy effect [69] - that is tight control initially, translates into lower risk for microvascular complications even if control deteriorates at a later date. Thus decreasing the rate of decline in β-cell function may translate into improved glycemic control with less risk of hypoglycemia and lower incidence of long term complications.

It is now possible by HLA typing; measuring autoantibodies against β-cell antigens; and measuring first phase insulin secretion to identify individuals who are at 35 to 60 % 5 year risk for development of T1D [10;12]. If long term safety issues are resolved then it is likely that immune therapies like teplizumab will be used in at risk individuals to arrest the disease at an early stage and so prevent the development of diabetes.

It is the authors’ opinions that the current clinical trials will confirm teplizumab’s effectiveness in decreasing the rate of decline in β-cell function, and that the drug will be available for this indication within the next 5 years.

Box 1
Drug summary.

Acknowledgments

Declaration of interest:

This paper was sponsored by the University of California, San Francisco and NIH R21 AT002616-03.

Footnotes

The authors state no conflict of interest.

Reference List

1. Wicker LS, Miller BJ, Mullen Y. Transfer of autoimmune diabetes mellitus with splenocytes from nonobese diabetic (NOD) mice. Diabetes. 1986;35:855–860. [PubMed]
2. Lampeter EF, McCann SR, Kolb H. Transfer of diabetes type 1 by bone-marrow transplantation. Lancet. 1998;351:568–569. [PubMed]
3. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu.Rev Immunol. 2005;23:447–485. [PubMed]
4. Lindley S, Dayan CM, Bishop A, et al. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes. 2005;54:92–99. [PubMed]
5. Phillips B, Giannoukakis N, Trucco M. Dendritic cell-based therapy in Type 1 diabetes mellitus. Expert Review of Clinical Immunology. 2009;5:325–339. [PubMed]
6. Martin AP, Rankin S, Pitchford S, et al. Increased expression of CCL2 in insulin-producing cells of transgenic mice promotes mobilization of myeloid cells from the bone marrow, marked insulitis, and diabetes. Diabetes. 2008;57:3025–3033. [PMC free article] [PubMed]
7. Yang LJ. Big mac attack: does it play a direct role for monocytes/macrophages in type 1 diabetes? Diabetes. 2008;57:2922–2923. [PMC free article] [PubMed]
8. Yang M, Charlton B, Gautam AM. Development of insulitis and diabetes in B cell-deficient NOD mice. J Autoimmun. 1997;10:257–260. [PubMed]
9. Martin S, Wolf-Eichbaum D, Duinkerken G, et al. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N.Engl.J Med. 2001;345:1036–1040. [PubMed]
10. Gianani R, Eisenbarth GS. The stages of type 1A diabetes: 2005. Immunol.Rev. 2005;204:232–249. [PubMed]
11. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial - Type 1. Diabetes Care. 2005;28:1068–1076. [PubMed]
. ** This study failed to show any benefit of oral or subcutaneous insulin in preventing development of type 1 diabetes in individuals at high risk for the disease. The study did however provide valuable information on the natural history of the disease and how to identify at risk individuals.
12. Skyler JS. Prediction and prevention of type 1 diabetes: progress, problems, and prospects. Clin Pharmacol.Ther. 2007;81:768–771. [PubMed]
13. Martin S, Pawlowski B, Greulich B, et al. Natural course of remission in IDDM during 1st yr after diagnosis. Diabetes Care. 1992;15:66–74. [PubMed]
14. Pasquali L, Fan Y, Trucco M, et al. Rehabilitation of adaptive immunity and regeneration of beta cells. Trends Biotechnol. 2006;24:516–522. [PubMed]
15. Cernea S, Pozzilli P New potential treatments for protection of pancreatic B-cell function in Type 1 diabetes. Diabet Med. 2008;25:1259–1267. [PubMed]
. * A review of different therapeutic options for type 1 diabetes.
16. Li L, Yi Z, Tisch R, et al. Immunotherapy of type 1 diabetes. Arch.Immunol.Ther.Exp.(Warsz.) 2008;56:227–236. [PubMed]
.* A review of different immunotherapies for type 1 diabetes.
17. Herold KC. Achieving antigen-specific immune regulation. J Clin Invest. 2004;113:346–349. [PMC free article] [PubMed]
18. O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med. 2004;10:801–805. [PubMed]
19. Lehmann PV, Forsthuber T, Miller A, et al. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature. 1992;358:155–157. [PubMed]
20. Ludvigsson J, Faresjo M, Hjorth M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N.Engl.J Med. 2008;359:1909–1920. [PubMed]
21. Gottlieb P, Eisenbarth GS, Kipnes M, et al. Interim Results of A Phase I/II Clinical Trial of a DNA Plasmid Vaccine (BHT-3021) for Type 1 Diabetes. EASD. 2008
22. Bougneres PF, Landais P, Boisson C, et al. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes. 1990;39:1264–1272. [PubMed]
23. Eisenbarth GS, Srikanta S, Jackson R, et al. Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Res. 1985;2:271–276. [PubMed]
24. Harrison LC, Colman PG, Dean B, et al. Increase in remission rate in newly diagnosed type I diabetic subjects treated with azathioprine. Diabetes. 1985;34:1306–1308. [PubMed]
25. Parving HH, Tarnow L, Nielsen FS, et al. Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study. Diabetes Care. 1999;22:478–483. [PubMed]
26. Silverstein J, Maclaren N, Riley W, et al. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N.Engl.J Med. 1988;319:599–604. [PubMed]
27. Stiller CR, Dupre J, Gent M, et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science. 1984;223:1362–1367. [PubMed]
28. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. Ortho Multicenter Transplant Study Group. N.Engl.J Med. 1985;313:337–342. [PubMed]
29. Cosimi AB, Colvin RB, Burton RC, et al. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N.Engl.J Med. 1981;305:308–314. [PubMed]
. * First clinical trial demonstrating that OKT3 can reverse ongoing renal-allograft rejection
30. Kung P, Goldstein G, Reinherz EL, et al. Monoclonal antibodies defining distinctive human T cell surface antigens. Science. 1979;206:347–349. [PubMed]
31. Vigeral P, Chkoff N, Chatenoud L, et al. Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients. Utilization of OKT3 as the sole immunosuppressive agent. Transplantation. 1986;41:730–733. [PubMed]
32. Davis MM, Chien YH. T Cell Antigen Receptors. In: Paul WE, editor. Fundamental Immunology. edn Sixth. 1999. pp. 341–366.
33. Thistlethwaite JR, Jr, Stuart JK, Mayes JT, et al. Complications and monitoring of OKT3 therapy. Am.J Kidney Dis. 1988;11:112–119. [PubMed]
34. Abramowicz D, Schandene L, Goldman M, et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation. 1989;47:606–608. [PubMed]
35. Alegre M, Vandenabeele P, Flamand V, et al. Hypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice: role of tumor necrosis factor. Eur.J Immunol. 1990;20:707–710. [PubMed]
36. Chatenoud L, Legendre C, Ferran C, et al. Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome--dosage and kinetics prerequisites. Transplantation. 1991;51:334–338. [PubMed]
37. Ferran C, Sheehan K, Dy M, et al. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur.J Immunol. 1990;20:509–515. [PubMed]
38. Hirsch R, Gress RE, Pluznik DH, et al. Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells. J Immunol. 1989;142:737–743. [PubMed]
39. Alegre ML, Peterson LJ, Xu D, et al. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation. 1994;57:1537–1543. [PubMed]
. * Description of humanized FcR non-binding version of OKT3, teplizumab
40. Bolt S, Routledge E, Lloyd I, et al. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur.J Immunol. 1993;23:403–411. [PubMed]
. * Description of humanized FcR non-binding anti-CD3 antibody, otelexizumab
41. Chatenoud L, Thervet E, Primo J, et al. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc.Natl Acad Sci.U.S.A. 1994;91:123–127. [PubMed]
. **First report to show that short treatment of anti-CD3 antibody induces stable remission of established diabetes in the NOD mouse
42. Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol. 2003;3:123–132. [PubMed]
43. Chatenoud L. Progress towards the clinical use of CD3 monoclonal antibodies in the treatment of autoimmunity. Curr.Opin.Organ Transplant. 2009;14:351–356. [PubMed]
44. Herold KC, Bluestone JA, Montag AG, et al. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes. 1992;41:385–391. [PubMed]
45. Hughes C, Wolos JA, Giannini EH, et al. Induction of T helper cell hyporesponsiveness in an experimental model of autoimmunity by using nonmitogenic anti-CD3 monoclonal antibody. J Immunol. 1994;153:3319–3325. [PubMed]
46. Johnson BD, McCabe C, Hanke CA, et al. Use of anti-CD3 epsilon F(ab')2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation. J Immunol. 1995;154:5542–5554. [PubMed]
47. Hirsch R, Bluestone JA, DeNenno L, et al. Anti-CD3 F(ab')2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation. 1990;49:1117–1123. [PubMed]
48. Parlevliet KJ, Ten BI, Yong SL, et al. In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants. J Clin Invest. 1994;93:2519–2525. [PMC free article] [PubMed]
49. van Lier RA, Boot JH, de Groot ER, et al. Induction of T cell proliferation with anti-CD3 switch-variant monoclonal antibodies: effects of heavy chain isotype in monocyte-dependent systems. Eur.J Immunol. 1987;17:1599–1604. [PubMed]
50. Riechmann L, Clark M, Waldmann H, et al. Reshaping human antibodies for therapy. Nature. 1988;332:323–327. [PubMed]
51. Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol. 1997;158:2947–2954. [PubMed]
52. Belghith M, Bluestone JA, Barriot S, et al. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med. 2003;9:1202–1208. [PubMed]
53. Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol. 2003;3:123–132. [PubMed]
54. Chatenoud L, Salomon B, Bluestone JA. Suppressor T cells--they're back and critical for regulation of autoimmunity! Immunol.Rev. 2001;182:149–163. [PubMed]
55. Sakaguchi S. The origin of FOXP3-expressing CD4+ regulatory T cells: thymus or periphery. J Clin Invest. 2003;112:1310–1312. [PMC free article] [PubMed]
56. Walker MR, Kasprowicz DJ, Gersuk VH, et al. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25 - T cells. J Clin Invest. 2003;112:1437–1443. [PMC free article] [PubMed]
57. Bisikirska B, Colgan J, Luban J, et al. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest. 2005;115:2904–2913. [PMC free article] [PubMed]
58. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N.Engl.J Med. 2002;346:1692–1698. [PubMed]
. **First report of using a humanized FcR non-binding anti-CD3 antibody (teplizumab) in new onset type 1 diabetes
59. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes. 2005;54:1763–1769. [PubMed]
60. Herold KC, Gitelman S, Greenbaum C, et al. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol. 2009;132:166–173. [PMC free article] [PubMed]
61. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N.Engl.J Med. 2005;352:2598–2608. [PubMed]
. **First clinical report of using otelexizumab in new onset type 1 diabetes
62. Kong F, Chen CH, Cooper MD. Thymic function can be accurately monitored by the level of recent T cell emigrants in the circulation. Immunity. 1998;8:97–104. [PubMed]
63. Woodle ES, Xu D, Zivin RA, et al. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation. 1999;68:608–616. [PubMed]
64. Hering BJ, Kandaswamy R, Harmon JV. Insulin Independence after Single-Donor Islet Transplantation in Type 1 Diabetes with hOKT3y1(Ala-Ala), sirolimus and tacrolimus therapy. Am.J Transplant. 2001 suppl 1:180, 200.
65. Hering BJ, Kandaswamy R, Harmon JV, et al. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am.J Transplant. 2004;4:390–401. [PubMed]
66. TrialNet Investigators. Type 1 Diabetes (T1D) Clinical Trial of the Effects of Anti-CD3 and Exenatide on Loss of Insulin Production in Patients with Recent Onset of T1D and Individuals at High Risk. 2009
67. Utset TO, Auger JA, Peace D, et al. Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol. 2002;29:1907–1913. [PubMed]
68. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann.Intern.Med. 1998;128:517–523. [PubMed]
69. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N.Engl.J Med. 2000;342:381–389. [PMC free article] [PubMed]